to mark rare disease day on february 28, some of canada’s top rare disease advocates share how advocacy became a part of their lives, what they are fighting for and how they find optimism in difficult times.
mucopolysaccharidoses (mps) are rare, progressive genetic disorders where a specific enzyme is missing, preventing mucopolysaccharides from breaking down. there are seven distinct subtypes of the disorder, which means it can present itself in many ways, with frequent symptoms being enlarged liver and spleen, skeletal issues and vision impairment.
this interview has been edited for length and clarity.
what is the prevalence of mps?
globally, the number is one in 25,000 live births, however, some subtypes are very rare. for example, there are only a handful of patients across the globe with mps vii.
what are some challenges faced by the mps community?
it’s a little better now, but equitable access to treatment is one challenge. there aren’t many mps clinical trials — especially for gene therapy in canada — so it can be very challenging to get patients access to international sites for clinical trials. some forms of mps have neurocognitive presentations, and there are no treatments for these. there’s a lot of research being done in this area so we’re hoping in the next 10 years — hopefully even sooner — we’ll have therapies on the market for mps patients who are neurocognitively affected.